Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Core Insights - KYV-101 shows promising clinical activity in treating progressive multiple sclerosis, with robust CAR T-cell penetration into the central nervous system and improved expanded disability status scale scores [1][2] - The therapy maintains a tolerable safety profile, consistent with earlier observations from the first 100 patients treated [1][2] - Early data highlights the broader potential of KYV-101 within neuroimmunology autoimmune diseases [1][2] Company Overview - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with KYV-101 as its lead candidate [11] - The company is advancing KYV-101 through late-stage clinical development for conditions such as stiff person syndrome and myasthenia gravis, alongside ongoing trials for lupus nephritis [11] Clinical Trial Data - Phase 1 investigator-initiated trials (IITs) of KYV-101 in progressive multiple sclerosis are being presented at the 2025 ECTRIMS Congress [1][2] - Stanford Medicine and UCSF are leading studies that demonstrate the safety and efficacy of KYV-101, with no serious adverse events reported [3][6] - Data from Stanford's study indicates robust CAR T-cell expansion and penetration into the CNS, with evidence of immune reset in patients [4][5] - UCSF's study also shows stable to improved EDSS scores in patients, reinforcing the therapy's potential [7][8] Mechanism of Action - KYV-101 is a fully human, autologous CD19 CAR T-cell therapy designed for potency and tolerability, aiming for deep B-cell depletion and immune system reset [10] - The therapy's mechanism targets B cells, which play a significant role in the pathogenesis of multiple sclerosis [9]